Relief System
Volume management in congestive heart failure (diuretic-resistant)
Key Facts
About Relief Cardiovascular
Relief Cardiovascular is an early-stage innovator targeting a significant unmet need in heart failure: diuretic-resistant volume overload. The company is pioneering a new category of transcatheter, smart implant systems that combine autonomous hemodynamic monitoring with the ability to modulate venous return (preload) to improve decongestion. Backed by specialized cardiovascular investors and led by an experienced team, Relief aims to move beyond temporary solutions and pharmaceuticals to offer a durable, personalized, and adjustable device therapy. Its first-generation Relief System has entered initial clinical studies outside the United States, positioning the company at the forefront of next-generation heart failure device development.
View full company profile